Skip to main content
. Author manuscript; available in PMC: 2017 May 25.
Published in final edited form as: J Vitreoretin Dis. 2017 Jan 26;1(1):65–74. doi: 10.1177/2474126416683299

Figure 8.

Figure 8

Comparison of the treatment burden before and after dual therapy with the dexamethasone intravitreal implant and anti-VEGF agent. The mean total number of anti-VEGF injections in the 6 months after dual therapy (4.25 injections) was significantly decreased compared to the mean during the 6 months prior to dual therapy (5.33 injections) (p=0.0199). The mean injection-free interval during the 6 months following dual therapy (1.75 months) was significantly longer compared to that seen during the 6 months before dual therapy (1. 13 months) (p=0.0312).